# Analysis of the relationship between antidepressants and seizures based on the food and drug administration's adverse event reporting system database

**Authors:** Dan Zou, Qiaozhi Hu, Lei Yu, Bin Wu

PMC · DOI: 10.1016/j.clinsp.2025.100727 · Clinics · 2025-07-15

## TL;DR

This study finds that 14 antidepressants, including bupropion, are linked to increased seizure risk using FDA adverse event data.

## Contribution

The study identifies specific antidepressants with seizure risk using FAERS data and quantifies their relative risk.

## Key findings

- Bupropion shows the strongest seizure risk signal with the highest reporting odds ratio.
- TCAs like clomipramine and maprotiline are associated with elevated seizure risk.
- Mirtazapine is linked to seizure risk despite initially low reports.

## Abstract

•14 antidepressants show a significant seizure risk association in the FAERS analysis.•Bupropion shows the strongest seizure signal with the highest reporting odds ratio.•TCAs/tetracyclics elevate seizure risk, particularly clomipramine and maprotiline.•SSRIs/SNRIs require safety reconsideration as seizure risk persists.•Mirtazapine is linked to seizure risk despite low initial reports.

14 antidepressants show a significant seizure risk association in the FAERS analysis.

Bupropion shows the strongest seizure signal with the highest reporting odds ratio.

TCAs/tetracyclics elevate seizure risk, particularly clomipramine and maprotiline.

SSRIs/SNRIs require safety reconsideration as seizure risk persists.

Mirtazapine is linked to seizure risk despite low initial reports.

Antidepressants, a cornerstone of depression treatment, are increasingly scrutinized for their safety concerns. The seizure risk of antidepressants has garnered attention. However, the current research on the relationship between antidepressant use and seizures remains unclear, prompting this study to investigate potential associations using data from the FAERS database.

This study sought to assess the correlation between seizures and different antidepressants in individuals without pre-existing epilepsy or neurological comorbidities, as well as to explore potential variations in the occurrence of adverse events linked to each specific antidepressant drug.

A disproportionality analysis was conducted to identify potential risk indicators within the FAERS database. Signals were detected using both the Reporting Odds Ratio (ROR) via the frequency approach and the Information Component (IC) through the Bayesian approach.

A total of 15,940,383 FAERS reports from January 1, 2004, to December 31, 2023, were analyzed. 14 antidepressant drugs were associated with seizures, as defined by 41 preferred terms.

This study identified 14 antidepressant drugs that showed significant associations with seizures. Bupropion had the highest seizure ROR among the antidepressant drugs evaluated in this study.

## Linked entities

- **Chemicals:** bupropion (PubChem CID 444), clomipramine (PubChem CID 2801), maprotiline (PubChem CID 4011), mirtazapine (PubChem CID 4205)

## Full-text entities

- **Diseases:** epilepsy (MESH:D004827), seizure (MESH:D012640), depression (MESH:D003866)
- **Chemicals:** Bupropion (MESH:D016642)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12281246/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12281246/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12281246/full.md

---
Source: https://tomesphere.com/paper/PMC12281246